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Background: Understanding the cost-effectiveness and affordability of interventions to reduce maternal and
newborn deaths is critical to persuading policymakers and donors to implement at scale. The effectiveness of
community mobilisation through women’s groups and health facility quality improvement, both aiming to
reduce maternal and neonatal mortality, was assessed by a cluster randomised controlled trial conducted
in rural Malawi in 2008–2010. In this paper, we calculate intervention cost-effectiveness and model the
affordability of the interventions at scale.
Methods: Bayesian methods are used to estimate the incremental cost-effectiveness of the community and
facility interventions on their own (CI, FI), and together (FICI), compared to current practice in rural Malawi.
Effects are estimated with Monte Carlo simulation using the combined full probability distributions of intervention
effects on stillbirths, neonatal deaths and maternal deaths. Cost data was collected prospectively from a provider
perspective using an ingredients approach and disaggregated at the intervention (not cluster or individual) level.
Expected Incremental Benefit, Cost-effectiveness Acceptability Curves and Expected Value of Information (EVI) were
calculated using a threshold of $780 per disability-adjusted life-year (DALY) averted, the per capita gross domestic
product of Malawi in 2013 international $.
Results: The incremental cost-effectiveness of CI, FI, and combined FICI was $79, $281, and $146 per DALY averted
respectively, compared to current practice. FI is dominated by CI and FICI. Taking into account uncertainty, both CI and
combined FICI are highly likely to be cost effective (probability 98% and 93%, EVI $210,423 and $598,177 respectively).
Combined FICI is incrementally cost effective compared to either intervention individually (probability 60%, ICER $292,
EIB $9,334,580 compared to CI). Future scenarios also found FICI to be the optimal decision. Scaling-up to the whole of
Malawi, CI is of greatest value for money, potentially averting 13.0% of remaining annual DALYs from stillbirths, neonatal
and maternal deaths for the equivalent of 6.8% of current annual expenditure on maternal and neonatal health in
Malawi.
Conclusions: Community mobilisation through women’s groups is a highly cost-effective and affordable strategy to
reduce maternal and neonatal mortality in Malawi. Combining community mobilisation with health facility quality
improvement is more effective, more costly, but also highly cost-effective and potentially affordable in this context.
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Maternal [1], perinatal and neonatal mortality in Malawi
remain high [2]. Community and health facility-based
interventions are needed to reduce these deaths [3] in
Malawi and other high-burden countries in order to
achieve millennium development goals four and five [4].
The MaiKhanda cluster randomised controlled trial
(cRCT) in Malawi showed that combining community
mobilisation through women’s groups (CI) and health
facility-based quality improvement (FI) reduced neonatal
mortality by 22% (95% CI: −40%, +1%; p = 0.057) [5].
The community intervention on its own reduced peri-
natal mortality by 16% (95% CI: −28%, −3%; p = 0.020);
no significant effects of FI on its own were observed on
neonatal, perinatal or maternal mortality or of CI and
FICI combined on maternal mortality [5]. Given re-
source constraints in Malawi and other low-income set-
tings where these interventions might be appropriate,
policymakers need to know their cost-effectiveness and
affordability relative to available alternative interven-
tions. In this article we determine the cost-effectiveness
and affordability of the community and facility-based
interventions, both on their own (CI, FI), and in
combination (FICI), as implemented by MaiKhanda in
three central region districts of Malawi between 2007
and 2010.
We used a similar approach to costing as in other,
similar trials with women’s groups as one of the inter-
ventions [6-9]. In evaluating the benefits, we focus on
the primary outcomes of the interventions [10], extend-
ing the analysis reported in the trial paper [5] by taking
into account all of the cRCT-measured effects on still-
births, neonatal deaths and maternal deaths, irrespective
of statistical significance. We determine the probability
that each intervention is cost-effective at a range of
Willingness-to-pay (WTP) threshold values ($ per DALY
averted), including the per capita gross domestic product
(GDP) of Malawi, and calculate the Expected Value of
Perfect Information [11] to determine whether reducing
uncertainty in the cRCT effect parameters is worthwhile.
We complement our cost-effectiveness analysis with
analyses of affordability [12] in relation to the number of
potential beneficiaries in Malawi and available govern-
ment and donor budgets for the interventions.
Methods
In any cost-effectiveness analysis it is important to consider
the alternatives being compared, perspective, time-horizon
and discounting, component parts of the measures of the
costs and effects of the intervention, and how all of these
could vary [10]. Each of these is detailed below, along with
details of how uncertainty surrounding measures was
assessed. This section finishes with details of the mathem-
atical and statistical analyses undertaken and outcomemeasures reported. Our reporting conforms to the
CHEERS statement [13].Study setting
Malawi is a low-income, predominantly rural country in
the rift valley of south-eastern Africa. It had an esti-
mated population of 16.4 million people in 2013 [14].
Gross Domestic Product (GDP) per capita was estimated
at $779.8 in purchasing-power-parity adjusted inter-
national dollars for 2013 [14]. Female literacy was esti-
mated at 67.6% in 2010 [2] and female life expectancy at
birth at 54.8 in 2012 [14]. The MaiKhanda trial was
located in three central region districts of Malawi:
Lilongwe, Kasungu and Salima, and involved the ran-
domisation of health facility catchment populations
(clusters) to either, both or none of the interventions, in
a two-by-two factorial design [5,15].Alternatives compared
Each intervention is described in detail elsewhere [5,15].
Briefly, the community mobilisation intervention (CI)
involves participatory women’s groups mobilising com-
munities around maternal and neonatal health, using
volunteer facilitators supported by programme staff. The
groups follow an ‘action cycle’ , adapted from previous
studies [16-19], to identify and prioritise maternal and
neonatal health problems, decide upon locally appropri-
ate solutions, advocate for, implement and evaluate
the solutions. 729 groups were set up, facilitated by 81
volunteers (who received bicycles, monthly bicycle
maintenance allowances and supervision from 9 salaried
MaiKhanda staff ). Each group met monthly for an
average of 16 times and strategies adopted included
bicycle ambulances, vegetable gardens, health education,
village savings and loans, and bednets.
The health facility quality improvement intervention
(FI) involves ‘breakthrough series collaboratives’ [20]. A
quality improvement team was set up in each health
centre in order to share quality improvement ideas
within and across facilities and implement them within
their facilities in action periods. The intervention in-
cluded training staff in quality improvement techniques,
implementing change packages [21] focused on obstetric
and newborn care, conducting death reviews [22], lead-
ership training and specific additional protocol-based in
situ clinical trainings. No new staff were recruited and
no additional financial resources were provided to the
facilities as part of the intervention evaluated in the trial.
The interventions were implemented in addition to
current Government of Malawi Ministry of Health
(MoH) practice in maternal and neonatal health. The in-
cremental cost-effectiveness of the CI, FI and FICI inter-
ventions, were therefore calculated relative to ‘current
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and control areas.Perspective
Cost effectiveness is calculated from the provider per-
spective. In any future scale-up of the intervention
throughout Malawi, this will likely be the MoH. Given
that the MoH relies significantly on donor funding, we
have taken account of potential future trajectories for
donor funding in our assessment of the affordability of
the interventions.Costs
Women’s groups are a community intervention for
which resource use can only be meaningfully identified
at the community level. Therefore economic costing
guidelines, which have been developed for individual-
level variation in resource use, need to be adapted [6]. In
our case, both interventions were implemented for each
intervention arm as a whole, not cluster-by-cluster,
meaning that it was not possible to identify cluster-level
variation in resource use.
The main source of economic cost data were the financial
accounts of MaiKhanda, the Malawian non-governmental
organisation (NGO) implementing the interventions. Costs
were also incurred by overseas implementing partners: the
US-based Institute for Healthcare Improvement (IHI) and
the UK-based Women and Children First (WCF). Key
informant interviews and project documents were used to
assist in the conversion of accounting costs to economic
costs. We were unable to cost health worker’s time, there-
fore our costing of the FI is not a full economic-costing.
For reasons stated in the discussion we believe it still re-
flects the replicable costs of implementation. Research
costs, which were collected via a separate accounting sys-
tem and therefore easily separable, are excluded for the
purposes of this analysis. Project accounts were used to
identify staff, material and capital costs directly associated
with setting up and implementing the CI and FI interven-
tions. We also identified joint (programme) costs, which
could not be directly allocated to either intervention or to
the other trial activities (stakeholder engagement, monitor-
ing and evaluation, process evaluation, and research). A
proportion of joint costs each year was allocated to the CI
and FI interventions using joint cost allocation rules, which
were arrived at through discussion with key informants [6].
Capital costs were annualized over the expected lifespan as-
suming constant linear depreciation.
Costs were converted to 2013 values using the Malawi
consumer price index and to international dollars using
the implied 2013 purchasing-power parity conversion
factor for GDP (1 INT$ = 105.8 Malawi Kwacha) [14].
Costs incurred in Pounds Sterling (GBP; £) and UnitedStates Dollars (USD, $) were also converted into 2013
international dollars.
Not all external staff costs were available from ac-
counting systems. Key informants were interviewed to
estimate the costs of external experts using either their
annual salary when applicable, or using the daily rate
(averaged over the study period) of each named expert
involved with the trial, the number of stays, and dur-
ation of each visit. External costs estimated in this way
amounted to 607 days and are reported separately due
to the different degree of accuracy compared to staff
costs for which programme accounts data was available.
As intervention costs could not be disaggregated by
trial cluster or arm, the cost of the combined FICI arm
had to be estimated from the costs of the FI and CI in-
terventions, both implemented across two arms. We as-
sumed conservatively no economies of scope, in the
sense that the cost of FI in the FI only arm was equal to
the cost of FI in the combined FICI arm; and similarly
for CI. In practice, when FICI costs are doubled to per-
tain to the same size population as FI and CI (Table 1),
this is equivalent to assuming that the cost of the com-
bined intervention is the sum of the two. In the trial
analysis this is likely to be an accurate reflection of real-
ity, because the CI and FI teams worked across trial
arms. Our implementation design did not allow us to
investigate possible cost savings that may arise from
complementarity when implementing both interventions
outside a trial setting.
Effects
The benefits of the interventions were assessed over the
duration of the trial period: 1st October 2008 to 31st
December 2010. The effects of the CI, FI and FICI inter-
ventions on maternal, neonatal and perinatal mortality
have been previously reported as odds ratios (OR) [5].
The trial did not collect data on individual-level covari-
ates except mortality. In this paper we use cluster-level
totals of births, stillbirths, neonatal deaths and maternal
deaths, along with cluster-level covariates (district and
urban/rural cluster stratification and intervention desig-
nation of the clusters (CI, FI, FICI, control) to determine
overall effects on stillbirths and neonatal deaths com-
bined (baby mortality), and maternal deaths (mother
mortality) [5]. These were modelled in separate logistic
regression equations and combined to give an overall
measure of effect.
Due to the two-by-two factorial nature of the trial
[5], we first modelled the effects of two-arm CI vs.
two-arm ‘no CI’ and two-arm FI vs. two-arm ‘no FI’ ,
and then modelled the effects of one-arm FICI vs.
one-arm control. The results of each model were
saved in order to compare CI, FI and FICI in one cost-
effectiveness analysis.
Table 1 Costs and effects of community, facility and combined interventions
Parameter Community intervention
(CI; 2 arms)
Facilities intervention
(FI; 2 arms)
Combined FICId Source
(1 arm) (2 arms)
Total population
(babies and mothers)
1,200,000 (108,000) 1,200,000 (108,000) 600,000 (54,000) 1,200,000 (108,000)
Comparisons data used for: CI vs. current practice;
CI vs. FI vs. FICI
FI vs. current practice;
CI vs. FI vs. FICI
FICI vs. current
practice
CI vs. FI vs. FICI
Start-up cost, beginning ($) 362,083 362,860 362,472 724,943 MaiKhanda
accounts
Maintenance costs, annual,
on-going ($ per year)
27,250 25,328 26,289 52,578
Annual implementation
costs ($ per year)
2,068,997 2,026,811 2,047,904 4,095,808
External costs ($ per year) 120,067 272,017 196,042 392,084 Estimateda
Total cost
(27-month trial period)
5,348,791 5,592,212 5,470,501 10,941,002 Start-up, recurring
and external costs
Baby mortality
(OR, 95% CI)
0.873 (0.774, 0.982) 0.954 (0.846, 1.070) 0.841 (0.707, 0.992) 0.841 (0.707, 0.992) model of cRCT data
(Additional file 1)
Mother mortality
(OR, 95% CI)
0.957 (0.494, 1.657) 1.228 (0.652, 2.135) 1.287 (0.488, 2.839) 1.287 (0.488, 2.839)
Babies savedb
(mean, 95% CI)
772 (109, 1384) 291 (−439, 974) 475 (23, 880) 951 (46, 1760)
Mothers savedb
(mean, 95% CI)
18 (−270, 210) −97 (−480, 148) −62 (−397, 112) −124 (−793, 223)
DALYs avertedc
(mean, 95% CI)
67361 (8808, 121508) 19901 (−44769, 80586) 37590 (−4642, 74618) 75180 (−9284, 149236)
$ constant 2013 international dollars; OR = Odds Ratio (mean); 95% CI = 95% Credibility Interval (2.5th centile, 97.5 centile); DALY = Disability Adjusted Life Year.
aFrom specific expatriate staff grades, percentage full-time and length of time working on the project, travel and hotel costs.
bOut of 108,000 for CI and FI, which is the estimated total population of babies and mothers in the relevant groups of two trial arms (CI, no CI, FI, no FI) in
27 months (2.25 years). This is the estimated total population of 1,200,000 (based on average size of health centre catchment area (cluster) [5]) multiplied by an
estimated Crude Birth Rate (CBR) of 0.04 per person per year [2] for 2.25 years. For combined FICI it is out of 54,000, the estimated total population of babies and
mothers in the relevant groups of one trial arm (FICI and control [5]).
c86.0 DALY averted per baby saved and 53.27 DALY averted per mother saved, see text for explanation.
dNote that the estimated costs and effects for FICI (first FICI column) were doubled (second FICI column) in order to compare the cost-effectiveness of FICI with
the cost-effectiveness of CI and FI (Figure 4).
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and mother mortality obtained from the models to ‘deaths
averted’ using the control area mortality rate and the
number of live births, assumed to be 54,000 in each of the
four arms. The number of births is an approximation be-
cause the population under surveillance was about 10-
15% of the total population living in the intervention area.
The number of deaths averted was then converted to
Disability Adjusted Life Years (DALYs) averted. The num-
ber of stillbirths and neonatal deaths averted was multi-
plied by 86.0, the standard life expectancy at birth used in
the Global Burden of Disease 2010 study [23]. The num-
ber of maternal deaths was multiplied by 53.27, the
remaining standard life expectancy of females aged 30
[24], the median age of maternal death in Malawi in 2010
[2]Table 16.3, page 222. As a sensitivity analysis, and as recom-
mended by Polinder et al. [25], we also calculated ‘local-
ised-DALYs’ using remaining healthy life expectancies
specific to Malawi: 45.0 years, the healthy life expectancy
at birth in Malawi in 2010 [26] for stillbirths and neonatal
deaths averted, and 28.1 years, the healthy life expectancyat the median age of maternal death (30 years) in Malawi
in 2010 [2]Table 16.3, page 222 [26,27] for maternal deaths
averted. Consistent with the Global Burden of Disease
2010 study, no age weights or discounting were used
in the calculation of DALYs [23]. We do apply dis-
count rates to effects and costs in a modelling exer-
cise. Note that, as measured in the trial [5], we assume
all stillbirths are viable, and therefore apply the same
DALYs averted as for a neonatal death [28].
Analyses and outcome measures
We developed a Bayesian model to estimate the com-
bined effects of each intervention as described above.
We used Bayesian methods to take account of all of the
available information, particularly the information on
mortality averted, and to allow subsequent efficient and
direct calculation of cost-effectiveness estimates and re-
lated parameters for decision-makers [11]. Given a lack
of prior information on the effectiveness of the interven-
tions or the covariates in the model we set priors for all
model parameters to be zero (the log of an odds ratio of
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large uncertainty (variance of 10000 on the log scale).
Equivalent parameters for the baby and mother mortal-
ity equations were modelled as multivariate normal dis-
tributions to improve the efficiency of estimation [11].
We modelled the effects with JAGS [29] in R [30]. For
each model, 100,000 simulations were saved from two
chains of 510,000 simulations, with a burn-in of 10,000
that were discarded and thinning of only every 10th
simulation being saved to reduce autocorrelation [11].
The R package BCEA (Bayesian Cost Effectiveness Ana-
lysis) [31] was used with the estimate of total interven-
tion costs to produce the following four key aspects of
the results [11]. Additional file 1 contains the statistical
models, R code including all details related to priors and
initial values, and cluster-level data, used and should en-
able replication of our results.
1. Incremental cost-effectiveness ratios (ICERs) were
determined for CI, FI and FICI interventions, using
the following formula:
ICERð$ per DALYÞ ¼ C1−C0E1−E0 ¼ C1E1 ð1Þ
where C1 is the cost of the intervention in 2013 inter-
national dollars ($), E1 the effect of the intervention in
DALY averted, and C0 and E0 respectively the costs and
effects of the base case ‘current practice’ , both zero
because the ‘current practice’ costs and effects in the inter-
vention and control areas are assumed to be equal and to
therefore cancel each other out. For each comparison, the
100,000 simulations of E1 against the fixed C1 were plotted
on the cost-effectiveness plane and the ICER calculated.
E1 in equation (1) represents the mean effects of the inter-
vention from all 100,000 simulations. In a final three-way
comparison of CI, FI and FICI, ICER of FICI (C1, E1) and
FI (C1, E1) were each calculated relative to CI (C0, E0).
2. Expected Incremental Benefit (EIB) is the monetary
value of the net benefit of the intervention and was
determined by multiplying the number of DALYs
averted by the cost-effectiveness threshold (k) – the
maximum cost per DALY averted that the provider
might be willing to pay – and subtracting the differ-
ence in costs:
EIB $Þ ¼ k E1−E0ð Þ− C1−C0ð Þ ¼ kE1−C1ð ð2Þ
3. Cost-effectiveness Acceptability Curves (CEAC)
were calculated to show the probability that each
intervention is cost-effective in comparison tocurrent practice or each other, given the data
(following our use of the Bayesian framework) and
specified alternative k. Following others [11,12,32]
chapters 4 and 5, probabilities of cost-effectiveness were
calculated by determining the proportion of the
simulations in which the reference intervention was
more cost-effective than the comparator at a given
$-per-DALY threshold, repeating at a range of
threshold $-per-DALY values relevant to current
and potential government health spending in
Malawi, and plotting the results.
4. Expected Value of Information (EVI) was calculated
to quantify the monetary ($) value of reducing
uncertainty in the model parameters through
additional research. It is calculated by comparing the
EIB of the current decision with the probable EIB
given additional information on the model
parameters. EVI can be compared with the EIB
(both at specified values of k) to determine if
spending additional money on research to reduce
parameter uncertainty might be worthwhile.
Trial-based cost-effectiveness
Firstly, we report ICER, EIB, CEAC and EVI using the
trial data. We assume the costs to be point estimates for
the whole intervention prospectively collected during
start-up and implementation (56 months) and the effects
as distributions, estimated from the cRCT during the
27-month intervention period, as detailed above, and no
discounting of costs or effects.
Scale-up modelling exercise: Time-horizon and
discounting
Secondly, we assess affordability and undertake a model-
ling exercise of cost-effectiveness and affordability based
on future scenarios with differing available budgets, dis-
count rates, and time-horizons. Costs were collected
over a period of 4.6 years from May 2006 to December
2010. Activities in the two years before the start of the
trial period in October 2008, included hiring and train-
ing research and implementation staff, developing and
piloting the interventions, and introducing the interven-
tions into village communities through the traditional
leadership hierarchy. All costs incurred in 2006 were
classified as start-up costs. When scaling up the inter-
vention many of the activities conducted during this
period, such as intervention design, would not be repli-
cated. As such, only those start-up activities relevant to
the intervention implementation, such as the purchase
of vehicles and equipment and the hiring and training of
staff to run the intervention, are included in the scale-up
model. In 2007 50% of costs were classified as start-up
because intervention implementation and the trial base-
line period began in July 2007. Between July 2007 and
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sified as maintenance costs, with all other intervention-
associated costs classified as implementation costs. The
economic costs for all start up, maintenance and imple-
mentation activities required to replicate the intervention
at scale, have been included in this model.
As recommended by the WHO, we go on to model
cost-effectiveness over a 10-year time horizon [33].
Start-up costs from 2006 and 2007 are included in year
one costs of the model. Maintenance costs for activities
such as the regular recruitment and (re)training that
would be required throughout an intervention, were
annualised and included for each of years one to ten.
Implementation costs for the 2007–2010 implementa-
tion period were annualised by dividing their total by the
length of the trial period – the period when the effects
were measured (2.25 years), and included for each of
years one to ten. The trial period length was used to
align costs with effects. Effects were also annualised by
assuming the same effect per year as estimated over the
2.25 years of the trial period. Annualisation of costs and
effects enables us to model cost-effectiveness over time
horizons different to the observed trial period. We then
applied the 3% annual discount rate recommended by
the WHO [33], to the total costs for years two to ten. In
sensitivity analysis, the time horizon was varied from 5
to 20 years, to reflect short-term and longer-term
decision-making time frames, and to explicitly model
the effect of intervention duration on the spread of setup
and capital expenditure (among other fixed costs). The
discount rate on costs was varied between 0% and 10%
to reflect a plausible range of scenarios. Future effects
(health benefits) were discounted at 2% and varied from
0% to 3% in different sensitivity analyses. It is likely that
the discount rate for health benefits would be lower than
the discount rate for costs [34,35], especially if the ($ per
DALY) cost-effectiveness threshold increases in future,
in-line with expected per-capita GDP growth [36]. Con-
sistent with best practise and the Gates Reference Case
[37], we also include the 3% discount rate for effects to
show results of scenarios with equal discount rates.
Affordability
Given the fixed costs of the interventions (no uncer-
tainty in the costs due to no individual- or cluster-level
costs being available) the affordability of the interven-
tions in a hypothetical scale-up to the whole of Malawi
was estimated deterministically. This was done using the
following estimates of the available budget for maternal
and neonatal health (MNH) in Malawi. In 2010, annual
per capita expenditure on health in Malawi was $228.7
in constant 2013 international dollars, and the total
population was 15,013,694 [14]. The percentage of total
health expenditure spent on maternal and neonatalhealth was estimated to be 11.95% in 2010 [38]. Multi-
plying these figures yields an estimate of $410,354,347
for the total expenditure on MNH in Malawi in 2010.
This estimate frames the available budget for affordabil-
ity calculations.
To estimate the cost of scaling-up each intervention to
the whole of Malawi we multiplied the annualised cost
by a ratio of the total population of mothers and babies
(estimated from the total population and the crude birth
rate) to the population of mothers and babies covered in
the trial, for that intervention. We then present afford-
ability as a percentage of total annual MNH expenditure.
2010 was used for these analyses due to data availability,
especially for estimation of DALYs averted from current
practice interventions. We used the latter to compare
percentage expenditure with expected percentages of
remaining DALYs averted by the interventions in
scale-up scenarios across Malawi (Additional file 2,
and discussion).
Results
Table 1 summarises the costs and effects for each of the
three interventions. The community intervention cost a
total of $5,348,791 of which $362,083 were start-up
costs, $2,068,997 annual implementation costs, $27,250
annual maintenance costs and $120,067 were annual ex-
ternal (overseas) staff costs. The facility intervention had
similar start-up costs, higher external costs, but slightly
lower annual implementation costs, resulting in slightly
higher total costs for the trial period, of $5,592,212.
The mean newborn deaths (DALYs) averted by the
community, facility and combined interventions were
respectively estimated as 772 (66,409), 291 (25,048) and
951 (81,772). The mean effect of CI on maternal mortal-
ity was 18 deaths averted, while the mean effect of FI
and combined FICI was negative (97 and 124 extra
maternal deaths respectively), though the 95% credible
intervals were very wide. The combined effect was
67,361, 19,901 and 75,180 DALYs averted, with only the
2.5th centile of the posterior distribution of the effect of
the community intervention being above zero, denoting
a significant effect with 95% credibility. Additional file 1
contains full results for all model parameters and model
diagnostic statistics.
Figure 1 plots the ICER, EIB, CEAC and EVI results of
the community intervention compared to current prac-
tice. Figure 1a shows the results of each of the 100,000
saved Monte Carlo simulations on the cost-effectiveness
plane (note the constant costs but uncertain effects) and
shows the ICER of the community intervention in com-
parison to current practice to be $79 per DALY averted.
Figure 1b shows a linear increase in EIB as WTP
increases above the break-even point of the ICER. At a
WTP of $780 per DALY (approximately the WHO-
Figure 1 Community Intervention (CI) vs. current practice: a) cost effectiveness plane and Incremental Cost-Effectiveness Ratio (ICER),
b) Expected Incremental Benefit (EIB), c) Cost-effectiveness Acceptability Curve (CEAC), d) Expected Value of Information.
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ventions – the per capita GDP [33]) the EIB is
$47,192,509. Figure 1c shows the CEAC. At WTP thresh-
olds above the ICER of $79 per DALY averted the prob-
ability of cost-effectiveness increases past 50%, reaching
98% at a WTP of $780 per DALY. Figure 1d shows the
EVI reaches a maximum of around $900,000 when the
WTP threshold equals the ICER of $79 per DALY,
the point where we are most uncertain of the cost-
effectiveness. At the WTP threshold of $780 per DALY
the EVI is even lower at $210,423.
Figure 2 shows the results of the facility intervention
compared to current practice. The ICER is $281 per
DALY averted and the probability of cost-effectiveness
only increases to 66% at the per capita GDP WTP
threshold of $780 per DALY averted and does not reach
70% even at thresholds of $2500 per DALY. At $780 per
DALY averted the EIB is $9,930,509 and the EVI is
$5,851,010.
Figure 3 compares the facility and community inter-
ventions combined, with current practice. As expected,the ICER is between that of the individual community
and facility interventions, at $146 per DALY averted. At
a threshold of $780 per DALY averted the probability of
cost-effectiveness is 93%, the EIB is $23,849,857 (note
the population covered by the combined intervention is
half of that covered by each of the individual interven-
tions) and the EVI is $598,177.
Figure 4 shows the results of comparing the commu-
nity intervention with the facility intervention, and the
facility and community interventions combined. Com-
paring the community intervention to the facility inter-
vention, the ICER is -3 (Additional file 1). This means
that the community intervention strictly dominates the
facility intervention, as it is both more effective and less
costly than the facility intervention. At a WTP of $780
per DALY, it is 95% probable that the community
intervention is cost-effective compared with the facility
intervention.
Figure 4a shows the ICER for the community inter-
vention compared with the combined intervention, the
next most cost-effective of the three interventions. The
Figure 2 Facility Intervention (FI) vs. current practice: a) cost effectiveness plane and Incremental Cost-Effectiveness Ratio (ICER),
b) Expected Incremental Benefit (EIB), c) Cost-effectiveness Acceptability Curve (CEAC), d) Expected Value of Information.
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(i.e. the cost of FI), the mean expected incremental ef-
fect 11,967 DALYs averted, and the ICER is $292 per
DALY averted, suggesting that at WTP thresholds
above this, the combined intervention is the optimal
decision. Indeed at the threshold of $780 per DALY it
is 60% probable the combined intervention is incre-
mentally cost-effective compared to the community
intervention. At $780 per DALY the EIB for the com-
bined intervention is $9,334,580 more than that for
the community intervention, and the EVI is large at
$11,708,726.
Using local life expectancy to calculate DALYs averted
supports the same decisions at key threshold values.
Though the ICERs were larger and probabilities of cost-
effectiveness and EIB lower, all mean ICERs were below
the threshold of $780 per DALY and in the same order,
with CI having the lowest ICER when compared to
current practice, and FICI being the optimal interven-
tion when comparing all three at the $780 threshold
(Additional file 3).Scaling-up to cover all 1,201,906 estimated mothers
and babies each year in Malawi would cost an estimated
$27,729,225 and $29,078,474 per year for the community
and facility interventions respectively, and $56,807,699
for both combined (Table 2). These totals represent
6.8%, 7.1% and 13.8% of the estimated $410,354,347
total annual expenditure on MNH in Malawi in 2010
(Table 2).
With discount rates of 3% for costs and 2% for effects
and a 10-year time horizon of a proportional scale-up of
the annual intervention costs and effects from the trial
to the whole of Malawi, comparing CI, FI and FICI at a
cost-effectiveness threshold of $780 per DALY, FICI is
the optimal intervention, with an EIB of $603,598,757
and probability of cost-effectiveness of 83.9% compared
to CI (Additional file 4). Sensitivity analyses varying the
time horizon between 5, 10 and 20 years, the annual
cost discount rate between 0%, 3% and 10%, and the
annual effects discount rate between 0%, 2% and 3%
found, at the $780 per DALY threshold, FICI to
have the highest probability of cost-effectiveness in all
Figure 3 Facility and Community Interventions combined (FICI) vs. current practice: a) cost effectiveness plane and Incremental
Cost-Effectiveness Ratio (ICER), b) Expected Incremental Benefit (EIB), c) Cost-effectiveness Acceptability Curve (CEAC), d) Expected
Value of Information.
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probability of cost effectiveness (EIB: $286,587,031;
5 years, 0%, 3%) to 94.9% probability of cost effective-
ness (EIB: $1,654,218,349; 20 years, 10%, 0%; Additional
file 4). The ICER of FICI compared to CI (the threshold
value at which FICI becomes the optimal decision)
ranged from $103 to $322 across the 27 scale-up
scenarios (Additional file 4). FI was dominated in all
scenarios.
Discussion
This analysis measured and compared the cost-
effectiveness of the MaiKhanda interventions, relative
to current practice and to one another. We used novel
methods to consider the whole of the estimated distri-
butions of the effects of the interventions on maternal
mortality, neonatal mortality and stillbirths from the
trial [5]. We estimate the community intervention to
be most cost-effective, with an ICER of $79 per DALY
averted compared to current practice alone. This isfollowed by the combined FICI intervention with an
ICER of $146 per DALY averted compared to current
practice, and the facility intervention with an ICER of
$281. Comparing all three, the community interven-
tion is the optimal decision at WTP thresholds below
$292 per DALY averted. Above this, including at the
per capita GDP per DALY averted ‘highly cost-
effective’ threshold [33] of $780 the FICI intervention
is cost-effective.
At $56,807,699 per year for the whole of Malawi, FICI
is considerably more expensive than CI at $27,729,225.
Either amount, at 13.8% and 6.8% of the current MNH
budget (Table 2), respectively represents significant ex-
penditure for Malawi. Given the continuing high burden
of maternal and perinatal mortality and morbidity in
Malawi and the observed cost-effectiveness of interven-
tions such as CI and FICI an increase in the total MNH
budget is clearly required. This could be achieved either
via increased government funding following increased
economic growth or more efficient tax collection in
Figure 4 Community Intervention (CI) vs. Facility Intervention (FI) vs. Facility and Community Interventions combined (FICI): a) cost
effectiveness plane and Incremental Cost-Effectiveness Ratio (ICER), b) Expected Incremental Benefit (EIB), c) Cost-effectiveness
Acceptability Curve (CEAC), d) Expected Value of Information.
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additional funds are not forthcoming reallocation of
MNH funding away from current activities likely to be
less cost-effective than CI or FICI should also be
considered.
Our EVI analyses suggest further research is worth-
while to resolve remaining uncertainties surrounding the
CI or FICI decision. At the $780 per DALY WTP thresh-
old, the EVI of $11,708,726 is not significantly different
from the cost of the trial at $13,538,490 (note this in-
cludes the research costs of $2,597,487). It is clear that
the CI (in addition to current practice) is cost effective
compared with current practice only. Therefore, unless
the WTP threshold is very low, there is no need to
invest in additional research to resolve the remaining
uncertainties surrounding this decision. Delays in
implementing CI at this stage are more likely to result
in benefits foregone, in particular neonatal deaths and
stillbirths. The facilities intervention was dominated
by the community intervention and the combinedintervention, suggesting money would be better spent
first on scaling up the community intervention and
then the combined intervention.
Using natural history counterfactuals, as recom-
mended by WHO for estimating the cost-effectiveness
of current interventions [33], we estimate the cost-
effectiveness of ‘current practice’ interventions to be
roughly $51 per DALY averted (see Additional file 2
for assumptions and calculations). This is less than
our estimates (looking at the same three mortality
outcomes only) of the cost-effectiveness of the com-
munity intervention ($79 per DALY) and substantially
less than the combined intervention ($146 per DALY)
or the facility intervention ($281 per DALY).
However, the most cost-effective interventions are
likely to have already been funded to bring down the
mortality rates to their 2010 level, and more intensive
and expensive interventions are usually required to reduce
mortality rates further. Therefore the community inter-
vention in particular can be said to be comparatively cost-
Table 2 Scale-up and Affordability of the interventions in 2010
Trial (per year) Nationwide scale-up (per year) ratio
Population (mothers and babiesa) 96,000b 1,201,096c 12.51
CI annual implementation costd ($) 2,216,315 27,729,225 12.51e
FI annual implementation costd ($) 2,324,156 29,078,474 12.51e
FICI annual implementation costd ($) 4,540,471f 56,807,699 12.51e
CI cost per persong ($) 23.09 23.09 1
FI cost per persong ($) 24.21 24.21 1
FICI cost per persong ($) 47.30 47.30 1
Total MNH expenditure in Malawi ($) 410,354,347
per person expenditure on MNH in Malawi ($) 341.65
proportion of MNH budget spent on CI 6.8%
proportion of MNH budget spent on FI 7.1%
proportion of MNH budget spent on FICI 13.8%
$ constant 2013 international dollars; CI = Community Intervention; FI = Facility Intervention; FICI = Facility and Community Interventions combined;
MNH =Maternal and Neonatal Health.
aOnly one baby per mother per year assumed on average.
bThis is the estimated total population of 1,200,000 (based on average size of health centre catchment area (cluster) [5]) multiplied by an estimated Crude Birth
Rate (CBR) of 0.04 per person per year [2], multiplied by two to reflect the mother and the baby separately.
cTotal population of Malawi in 2010: 15,013,694 [14] multiplied by CBR of 0.04 multiplied by two.
dRecurring plus external costs (see Table 1).
eRatio of trial to national population applied to trial costs to estimate nationwide costs per year.
fThis is the recurring plus external costs of FICI from the trial multiplied by two to reflect what the cost of FICI would have been if in the same area (two arms) of
the trial as CI or FI (so that the trial to scale-up population ratio is still valid).
gMother and baby counted separately.
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terventions currently included in the Essential Health
Package (EHP) in Malawi (Additional file 5) [39,40] and
recommended to improve maternal and neonatal health
in Africa [41]. Also, assuming, based on the estimated
mortality rates in 2010 that there were 2,892,134 DALYs
from maternal deaths, neonatal deaths and stillbirths
remaining, it can be deduced that the CI, FI and FICI in-
terventions could have prevented 13.0%, 3.8% and 14.5%
of these remaining DALYs if scaled-up throughout the
whole of Malawi (see Additional file 2 for sources and cal-
culations). Compared to the additional 6.8%, 7.1% and
13.8% respective additional expenditures on MNH the CI,
FI and FICI interventions could entail (Table 2) this repre-
sents a particularly good investment for the CI.
Whether fiscal space is available to invest in the Mai-
Khanda interventions depends on competing budget pri-
orities and projections. It will also depend on donor
priorities given that 60% of health expenditure in Malawi
was donor-funded between 2002–2006 [42] and an esti-
mated 89% in 2013–2014 [43]. Our future projections
for scale-up to the whole of Malawi indicated that at the
$780 per DALY cost-effectiveness threshold FICI is likely
to be the optimal decision, and at thresholds lower than
$103, CI is likely to be optimal (Additional file 4).
We hope that including analyses of affordability
based on recent expenditure on MNH as well as cost-
effectiveness with comparison to the EHP will make
our study useful for policy makers in Malawi and helpthem to decide whether investment in and scale-up of the
MaiKhanda interventions are worthwhile. To aid decision-
makers we have determined cost-effectiveness in relation
to a range of $-per-DALY thresholds, with a focus on the
per capita GDP of Malawi, recommended by WHO to
represent ‘highly cost-effective’ interventions [33]. Al-
though there are alternative methods of threshold setting
[44], we believe this threshold to be valid and perhaps more
reflective of the current EHP than the more arbitrarily-set
threshold of $150-per-DALY (Additional file 5) [44]. We
also hope our study will be useful for researchers, particu-
larly because we have been transparent with our data,
methods and assumptions to enable replication and use of
our results.
Our study has three important limitations. Firstly, we
were not able to capture cluster-level variation in re-
source use because the interventions were not delivered
cluster-wise but taking all randomised clusters as one
intervention area. Therefore we were not able to take ac-
count of the correlation between costs and effects at the
cluster level. We are aware of recent recommendations
for cost-effectiveness analysis of cRCTs [45,46] that draw
attention to the clustering of costs. However, these rec-
ommendations are of limited relevance to us because
the recipient of the MaiKhanda interventions was the
community or health facility, not the individual
mother or child. Identifying individual-level resource
use would not be conceptually meaningful (nor pos-
sible) in our situation in which many members of the
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group nor had contact with a health facility.
Secondly, our cost analysis adopted a limited interven-
tion provider perspective. We did not include related
health sector costs, such as the costs of increased care-
seeking that may result from a combined ‘pull’ of the
supply side intervention (FI) and ‘push’ of the demand
side intervention (CI). However, the trial found no sig-
nificant differences in utilisation of health services for
childbirth across arms [5] supplementary figure; data on ante-
natal or postnatal care was not collected. Providing
cover for staff attending the Quality Improvement (QI)
workshops was not considered. Given chronic staff
shortages in Malawi [47] it is very unlikely that absent
staff would be covered. Importantly, the effect on mor-
tality of staff brought in to cover absent staff would also
remain unknown. Neither did we include potential cost
savings that may arise in particular in the FI intervention
as a result of a reduction in staff attrition. It is possible
that the time health workers spent on the quality im-
provement activities of FI whilst at work in their health
facilities could be spent on other, more effective, activ-
ities. This is an area for further research and we are not
aware of any existing economic evaluations of similar
interventions with time use data that explored this ques-
tion. Donations and volunteer inputs were also not in-
cluded. However, these were minimal, such as limited
drug and equipment donations to a few facilities. The
community intervention relied on volunteer women’s
group facilitators as an integral part of the intervention
and defining characteristic of the MaiKhanda trial. Given
costs were prospectively collected, the only major source
of uncertainty in our cost estimates was the allocation of
joint costs to each intervention. Based on the agreement
of the donor and the partner organisations implement-
ing each intervention, we chose an equal allocation of
joint costs for FI and CI based on the equal – propor-
tional to implementing staff number – allocation of of-
fice space and equal use of administrative staff and joint
programme resources. Joint costs were 46% of CI and
53% of FI costs, therefore introducing, say, +/− 5 per-
centage points uncertainty in the allocation rule would
result in the total cost estimates for each intervention
varying by +/−2.3% and +/−2.7% respectively. Assuming
symmetrical uncertainty and that each intervention
would have an equal (proportional to need) joint cost
allocation as per the implementing programme part-
ner’s agreement, the ICERs for each intervention –
which as a ratio of the expected value of two uncertain
parameters have no uncertainty themselves - would
remain unchanged.
Thirdly, our analysis is likely to present an underesti-
mate of the full effects of the interventions. In particular,
estimating the effects on maternal and neonatalmorbidity was beyond the scope of this study. More-
over, the community intervention could empower
women and other members of the community, and
improve a variety of areas of quality of life including
those related to physical and psychological health,
social relationships and the environment [48]. The fa-
cility intervention could improve staff morale, motiv-
ation and empowerment and reduce staff attrition.
Both interventions could also improve links between
communities and health facilities. Measurement of all
of these potential benefits were also beyond the scope
of the current study due to its resource constraints,
although small sample sub-studies on many of these
measures were undertaken [15,48].
We also made a number of assumptions within our
analyses. The international travel and salary costs of the
external technical experts that contributed to the com-
munity and facility interventions have been included as
recurring costs throughout the modelled time horizons.
From the perspective of the MoH these costs may be
determined less necessary if local experts could be used
instead at lower cost. However, as per the trial, local
experts may not be available, and even if available they
might steer the interventions in a different direction,
which could result in different effects as well as lower
costs. We have also assumed that the costs and effects
of each of the interventions increase proportionally
with any scale-up of the interventions. Further research
is needed on how the costs (and effects) of the
interventions may change at scale. For the costs,
economies-of-scale are possible via a number of
mechanisms including decreases in unit prices when
increased quantities of equipment and materials are
purchased, and cost-sharing resulting from the MoH
or other NGOs sharing activities in any scale-up.
However, given that the interventions are mainly reli-
ant on human resources (55% and 49% of the commu-
nity and facility intervention costs, respectively), such
economies-of-scale may not be significant. How the
process of scaling-up affects staff deployment should
nevertheless be investigated. Variations in prices by
region of the country may also be important when
estimating scale-up costs. Health effects may not be
independent of scale, especially if the population
coverage and density of the interventions is not kept
at the same level as the cRCT in the scale-up [9].
Complex interventions such as the MaiKhanda com-
munity and facility interventions are also unlikely to
be replicated in exactly the same way. Although pro-
cesses and function should be standardised to some
extent, exact content will depend on local context
[15,49], meaning costs and effects of any scale-up are
likely to be different to the trial-based estimates we
have used.
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should be considered along with other health system
goals such as equity and acceptability to stakeholders
[50]. Information on equity of distribution and accept-
ability of the interventions to different stakeholders re-
mains unavailable, although an on-going study [51] is
investigating the equity of the distribution of the effects
of the women’s group intervention [52] in Malawi.
Future research to refine our assumptions and address
some of the limitations of our study would be worth-
while. A cost-effectiveness analysis of all women’s group
trials and potential scale-up as reported in Prost et al.
[9] is in progress.
Conclusions
Community mobilisation through women’s groups is, ac-
cording to these analyses, both cost-effective and afford-
able, compares well with current interventions in Malawi
and could avert a large proportion of DALYs caused by
stillbirths, neonatal and maternal deaths considering the
proportion of the budget it would require. When com-
bined with facility quality improvement it is highly cost-
effective and affordable, and at a per capita GDP threshold
the combined intervention warrants scale-up throughout
Malawi. Additional research could reduce the remaining
uncertainty surrounding this decision and assist decision-
makers in similar settings that could also benefit from
these interventions.
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with ‘current practice’ interventions, cost-effectiveness of ‘current
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expectancies. The number of deaths averted (the effects of the
interventions) were converted to Disability Adjusted Life Years (DALYs)
averted. As the base-case, ‘standard’ life expectancy was used to calculate
DALYs. The number of stillbirths and neonatal deaths averted was
multiplied by 86.0, the standard life expectancy at birth used in the
Global Burden of Disease 2010 study [23]. The number of maternal deaths
was multiplied by 53.27, the remaining standard life expectancy of
females aged 30 [24], the median age of maternal death in Malawi in
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Additional file 4: Future Scale-up scenarios. Scale-up to the whole
population of Malawi, using the trial population to total population ratio
explained in Table 2 of the paper. Annual maintenance, implementation
and external costs were used from Table 1 of the paper, and were
discounted using the costs discount rate for the scenario and added tothe scaled-up beginning start-up costs. Effects were annualised by
dividing the estimates from the 27-month trial by 2.25, and discounted
according to the effects discount rate of the scenario. Note that all
models were run with only 20000 saved Monte Carlo simulations from 2
chains of 21000 simulations with a burn-in of 1000 and thinning of 2
(as compared to the 100,000 saved simulations from the main analysis), but
adequate convergence of these models was achieved (Additional file 1).
Additional file 5: How the cost Effectiveness of the MaiKhanda
interventions compares to the Essential Health Package currently
used in Malawi.
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